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Autophagy, a major clearance route for many long-lived proteins and organelles, has long been implicated in
cancer development. Myc is a proto-oncogene often found to be deregulated in many cancers, and thus is an
attractive target for design of cancer therapy. Therefore, understanding the relationship between anti-Myc strat-
egies and autophagy will be important for development of effective therapy. Here, we show that Myc depletion
inhibits autophagosome formation and impairs clearance of autophagy substrates. Myc suppression has an in-
hibitory effect on autophagy via reduction of c-Jun N-terminal kinase 1 (JNK1) and B-cell lymphoma 2 (Bcl2)
phosphorylation. Additionally, the decrease in JNK1 phosphorylation observed with Myc knockdown is
associated with a reduction in ROS production. Our data suggest that targeting Myc in cancer therapy might
have the additional benefit of inhibiting autophagy in the case of therapy resistance associated with
chemotherapy-induced autophagy.
INTRODUCTION
Macroautophagy (hereafter called autophagy) is an evolutionar-
ily conserved process for bulk degradation of cytoplasmic con-
tents. It involves the sequestration of portions of cytoplasm
through the formation of double-membraned autophagosomes,
which are subsequently targeted for degradation after fusion
with lysosomes. Under normal conditions, autophagy is main-
tained at a basal level (1), where it is essential for quality
control of the cytoplasmic environment through themaintenance
of energy balance and by eliminating dysfunctional organelles
and aggregate-prone proteins. Under stress conditions, such as
starvation and hypoxia, autophagy is induced as an adaptive re-
sponse, anddrives the catabolismofproteins, lipids andcarbohy-
drates for de novo biosynthesis of biomacromolecules, which
enables cells to meet their metabolic and energy demands (2).
Therefore, autophagy is crucial for conferring cytoprotective
effects and promoting cell survival under various stress
conditions.
Autophagy can be regulated via diverse pathways. For in-
stance, amino acid depletion can induce autophagy by inhibiting
the mammalian target of rapamycin (mTOR) (3). There are also
a number of mTOR-independent autophagy pathways (4,5).
In one of these, nutrient depletion leads to increased JNK1 activ-
ity, which phosphorylates B-cell lymphoma 2 (Bcl2) (6). This
phosphorylation decreases the inhibitory interaction of Bcl2
with the core autophagy protein, Beclin 1, thereby increasing
Beclin 1 activity. This, in turn, activates autophagy, since Beclin
1 activates the lipid kinase Vps34, vacuolar protein sorting 34,
which generates phosphatidylinositol 3-phosphate to enhance
autophagosome formation.
Dysregulation of autophagy can lead tomalfunction of cellular
processes and thus, contribute to pathological conditions, includ-
ing neurodegenerative disorders, metabolic diseases and cancer.
In fact, cancer was the first human pathology associated with
autophagy, as revealed by the discovery that expression of
Beclin 1 was down regulated in 40–75% of human breast and
ovariancancersdue tomonoallelicdeletionof thegene (7). Inadd-
ition, deletion of various regulators of autophagy, including Bax
interacting factor-1 (Bif-1), ultraviolet radiation resistance-asso-
ciated gene (UVRAG) and Atg4, has been shown to promote the
development of spontaneous tumours in mice (8,9). These
studies indicate that autophagy may protect against cancer
development.
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On the other hand, by virtue of its pro-survival function,
autophagy has also been suggested to contribute to cancer pro-
gression, especially in the late stages of disease. In particular,
tumour cells growing in poorly vascularized regions are
deprived of nutrients and oxygen for extended periods of time.
Activation of autophagy enables recycling of macromolecules
and organelles, thereby accommodating the acute energy
needs of cancer cells (10,11). Furthermore, autophagy has
been proposed as a common mechanism mediating therapeutic
resistance to various cancer therapies (12,13). Therefore, the
role of autophagy in tumourigenesis appears to be context-
dependent and dynamic with the evolution of tumour cells
during the course of cancer progression.
Cancer encompasses a group of diseases resulting from
genetic changes that lead to unregulated cell proliferation
and eventually invasive transformation. Deregulated expression
of c-Myc (hereafter referred to as Myc) is one of the most
common lesions occurring in human cancers of diverse origin
(14,15), as high levels of Myc can lead to uncontrolled cell ex-
pansion and malignant transformation (16). There is also emer-
ging evidence that established tumour cells may acquire a
dependency on Myc activity (17), and thus, inhibition of Myc
could represent a novel therapeutic strategy for Myc-induced
cancers. Indeed, Myc depletion by using small-interfering RNA
(siRNA), antisense oligonucleotides or phosphorodiamidate
morpholino oligomers (PMOs) has been shown to trigger cell
growth arrest and apoptosis in transformed cells as well as
reduced growth of tumour xenografts (18,19). Similar observa-
tions were made in in vivo studies, in which inhibition of Myc
in a preclinical murine model of lung adenocarcinoma induced
apoptosis, breakdown of the tumour microenvironment, fol-
lowed by rapid tumour regression (20). These data have led to
the development of promising strategies to allow down regula-
tion of Myc for cancer therapy, including the development of
transcriptional repressors (21).
In situations where Myc levels were elevated, autophagy
appeared to be decreased (22,23). This suggests that inactivation
of Myc will lead to an increase in autophagy, which may be less
than optimal for treating existing cancers. Therefore, under-
standing the effects of Myc depletion on autophagy is relevant
for the design of anti-neoplastic therapy, as autophagy modula-
tors and inhibitors are currently being investigatedas chemother-
apy strategies. Accordingly, we sought to understand the effects
ofMyc suppression on autophagy. Contrary to our expectations,
we showed that Myc knockdown or inhibition had a very clear
inhibitory effect on autophagy. We further elucidated that Myc
regulates autophagy through changes in JNK1 activity and phos-
phorylation of its downstream target, Bcl2. As conventional
cancer treatment often leads to development of resistance
towards therapy, it is intriguing to envisage Myc as a target in
which the issue of therapy efficacy and resistance can be simul-
taneously addressed.
RESULTS
Myc inhibition impairs autophagosome formation
To investigate whether Myc plays a role in autophagy, we first
performed siRNA knockdown of the gene and examined its
effects on microtubule associated protein 1 light chain 3
(LC3-II) protein levels. LC3-II is the only known protein to spe-
cifically associate with autophagosomes, and thus, it is widely
accepted as a marker for monitoring autophagy (24). LC3 is
first synthesized as a precursor in the form of pro-LC3. It is
then proteolytically processed into LC3-I, which remains as a
cytoplasmic protein and does not associate with autophago-
somes. LC3-I is subsequently conjugated with phosphatidy-
lethanolamine on autophagosomes to form LC3-II. LC3-II
levels robustly correlate with autophagosome numbers (24).
Themost commonmethod to assay for autophagy is by immuno-
blotting for LC3-II levels, normalized to actin or tubulin as the
loading control (25).
Knockdown of Myc in HeLa cells decreased LC3-II levels,
and this correlatedwith a reduction in endogenousMyc expres-
sion (Fig. 1A). To verify that this was not due to an off-target
effect of the smartpool siRNAs, we confirmed that LC3-II
levels were also decreased with two different oligos targeted
against Myc (oligos 1 and 2) (Fig. 1B). Since changes in
LC3-II levels may reflect alterations in either its rate of synthe-
sis or degradation, LC3-II levels were assessed in the presence
of saturating concentrations of Bafilomycin A1 (Baf A1). Baf
A1 is a lysosomal inhibitor that blocks the fusion of autophago-
somes to lysosomes, thereby preventing LC3-II degradation
(26). This allows for specific evaluation of changes in LC3-II
formation, without confounding changes in its degradation
(25).MycknockdowndecreasedLC3-II levels even in the pres-
ence of Baf A1, confirming that Myc affects autophagosome
formation rather than its degradation (Fig. 1C). Similar obser-
vationswere obtained inHEK293 cells (SupplementaryMater-
ial, Fig. S1A) and Myc knockout (2/2) rat fibroblasts
(Supplementary Material, Fig. S1B), in which Myc depletion
decreased LC3-II levels in both the absence and the presence
of Baf A1.
We went on to test a small molecule inhibitor of Myc,
10058-F4 (referred to asMyc-I,Myc inhibitor (10058-F4), here-
after). This compound appears to inhibit Myc both by disrupting
its dimerization with its obligate partner,Max, which is required
for transactivation of target genes and by reducing Myc mRNA
expression indifferent cell lines (27).Consistentwith thegenetic
data, chemical inhibition of Myc resulted in decreased LC3-II
levels in bothHeLa (Fig. 1D) andHEK293 cells (Supplementary
Material, Fig. S1C).
To exclude the possibility that the decrease in LC3-II levels
observed is due to suppression in the transcriptional activity of
Myc on LC3, Atg5 knockout (2/2) murine embryonic fibro-
blast (MEFs) were used. Atg5 2/2 MEFs lack the Atg5
protein that is required for the conversion of LC3-I to
LC3-II, and thus, only LC3-I can be detected in Atg52/2
MEFs. If there was less transcription of LC3 itself, then
lower LC3-I levels would be detected in Atg52/2 MEFs
upon Myc inhibition. We observed no change in LC3-I
levels in Atg52/2 MEFs treated with an Myc inhibitor, sug-
gesting that Myc inhibition does not result in reduced tran-
scription of LC3 (Fig. 1E).
In addition to immunoblotting, an alternative approach to
assess autophagy is by immunofluorescence. For this, we used
HeLa cells stably expressing GFP-LC3, in which GFP-LC3
associated with autophagosomes appears as green puncta. We
observed that Myc knockdown decreased the number of
GFP-LC3 puncta (Fig. 1F).
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We also assessed the numbers of double FYVE (zinc finger
domainnamed after four cysteine-rich proteins:Fab1 (yeast ortho-
logue of PIKfyve), YOTB, Vac 1 (vesicle transport protein), and
EEA1) domain-containing protein (DFCP1) vesicles. DFCP1
labels phosphatidylinositol-3-phosphate (PI3P) on autophagosome
precursors, called omegasomes (28). Consistent with an inhibition
ofautophagosomeformation,Mycknockdowndecreased themean
number of GFP-DFCP1 vesicles per cell in HEK293 (Fig. 1E).
Figure 1.MYCRNAi knockdown decreases LC3-II levels. (A) (Left panel) HeLa cells subjected to control or Myc siRNA knockdown for 72 h were lysed and ana-
lysedbywesternblotting.Westernblot shows theknockdownefficiencyofMycprotein.Graph showsquantificationof theLC3-II/actin ratio.EndogenousLC3-IIwas
quantified by densitometry analysis and normalized to actin. Relative protein levelswere expressed as a percentage relative to the control cells, whichwere set to 100.
(Middle panel) HeLa cells subjected to control or deconvolutedMyc oligo (oligos 1 and 2) siRNA knockdown for 72 h were lysed and analysed by western blotting.
Western blot shows the knockdown efficiency of Myc protein. Graph shows quantification of the LC3-II/actin ratio. (Right panel) HeLa cells subjected to control or
Myc siRNAknockdown for 72 hwere treatedwith 400 nM bafilomycinA1 (BafA1) orDMSOduring the last 4 h and quantified as above. Graph shows quantification
of the LC3-II/actin ratio. SE, short exposure; LE, long exposure. (B) HeLa cells treatedwith 60 mMMyc inhibitor (Myc-I) for 16 hwere assessed for LC3-II levels by
western blotting.Graph showsquantification of theLC3-II/actin ratio. (A andB) The values represent themean+ standard error of themean (SEM)of the percentage
of LC3-II/actin from three independent experiments. Data for comparison between the two groupswere analysed by using a two-tailed t-test as described inMethods
section, ∗P, 0.05; ∗∗∗P, 0.0005. Statistical significance for comparison betweenmore than two groupswas analysed by one-wayANOVA,withDunnett post hoc
test. (C)Atg52/2MEFs treatedwith 60 mMMyc inhibitor (Myc-I) for 16 hwere assessed for LC3-I levels bywestern blotting. (D) HeLa cellswith stable expression
of GFP-LC3 were subjected to control or Myc siRNA knockdown for 72 h and fixed for quantification of LC3 dots. The number of LC3 dots was quantified by auto-
mated counting (see theMethods section). Representative images of the GFP-LC3 cells are shown. Graph shows quantification of the percentage of mean GFP-LC3
dots per cell relative to the control cells, which were set to 100. At least 500 cells were counted per sample and the values represent the mean+ standard error of the
mean (SEM) of the percentage of mean GFP-LC3 dots per cell from three independent experiments. ∗P , 0.05. Scale bar, 10 mm. (E) Hek293 cells with stable ex-
pression of GFP-DFCP1 were transfected with control or Myc siRNA for 72 h and fixed for counting of GFP-DFCP1 vesicles under a confocal microscope. Repre-
sentative images of theGFP-DFCP1 cells are shown.Graph shows quantification of the percentage ofmeanGFP-DFCP1 vesicles per cell relative to the control cells,
whichwere set to 100. At least 100 cells were counted per sample and the values represent the mean+SEMof the percentage of mean GFP-DFCP1 vesicles per cell
from three independent experiments. ∗P, 0.05.
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Myc inhibition causes autophagy substrate accumulation
Having established that Myc inhibition impairs autophagosome
formation, we next assessed the functional effects of this on
autophagy substrate accumulation. p62 (SQSTM1/sequestome1)
is a widely characterized endogenous autophagy substrate
(29,30).Consistentwith a decrease inLC3-II levels,Myc knock-
down in HeLa cells increased p62 levels (Fig. 2A). p62 levels
were also elevated in Myc 2/2 rat fibroblasts, compared with
wild-type (WT) controls (Supplementary Material, Fig. S2).
To validate that this was not predominantly a consequence of
Myc on p62 transcription, U2OS cells stably expressing
Halotag-p62 were used. The cells were labelled with a Halotag
fluorescent ligand before they were treated with Myc-I. The
Halotag ligand forms a covalent bond and binds irreversibly to
the Halotag protein. This enables a fixed pool of Halotag-p62
protein to be labelled and its levels can be monitored over time
after labelling in a chase period which is independent of any
changes in protein synthesis (31). Inhibition of Myc during the
chase period resulted in more labelled Halotag-p62 levels
remaining in comparison to controls, consistent with decreased
clearance and autophagy impairment (Fig. 2B). To further
confirm if the accumulation of p62 was due to attenuation in
its clearance rate, HEK293 cells with inducible expression of
GFP-p62 were subjected to knockdown experiments with Myc
or control siRNAs. After siRNA transfection, the expression of
GFP-p62 was induced for 24 h before being turned off and we
assessed the amount of GFP-p62 that was cleared over time, at
the time its expression was turned off (t ¼ 0), and 24 h after
switching-off (t ¼ 24). Myc knockdown caused a reduction in
the degradation rate of GFP-p62 over time, as evident by the
ratio of GFP-p62 remaining at t ¼ 24 relative to t ¼ 0
(Fig. 2C). Similarly, impaired GFP-p62 clearance was also
observed with Myc-I (Fig. 2D).
Asp62expressionmight be affectedbyvarious factors that are
unrelated to autophagy (32), we also assessed other proteins that
are known autophagy substrates such as tau (33). For this
purpose, complementary DNA (cDNA) constructs encoding
tau fused with a photo-switchable fluorescent protein, Dendra,
were transiently transfected into HeLa cells. Dendra tags can
be irreversibly photo-converted from green to red fluorescence
by exposure to 405 nm light source. Converted forms of
Dendra-tau serve as a fixed pool of substrate proteins that can
be monitored over time after photo-switching. Myc knockdown
slowed the degradation of converted Dendra-tau, further
confirming the data obtained with p62 degradation (Fig. 2E).
Likewise, treatment with Myc-I delayed clearance of converted
Dendra-tau relative to controls. A similar effect was observed
with Baf A1-treated cells (positive control), which blocks deg-
radation of autophagosomes (Fig. 2F). Taken together, these
findings demonstrate that Myc inhibition resulted in decreased
clearance of different types of autophagy substrates, consistent
with impairment in autophagy.
Myc inhibition affects autophagy via the JNK1-Bcl2
pathway
To investigate the molecular mechanism by which Myc modu-
lates autophagy,we first examined the effect ofMyc knockdown
on mTOR activity, which negatively regulates autophagy.
The activity of mTOR can be assayed by measuring the phos-
phorylation its downstream targets, such as p70S6 kinase or S6
ribosomal protein (1). Myc knockdown did not significantly
change the phosphorylation of p70S6 kinase (Fig. 3A) and S6
ribosomal protein (Fig. 3B), indicating that there are other path-
ways independent of mTOR mediating the effects of Myc on
autophagy.
To understand the link between Myc-modulated autophagy
and cancer, we tested whether the compromise of autophagy
resulting from Myc inhibition was mediated through changes
in Bcl2, since the unphosphorylated form of this protein inhibits
Beclin 1 to decrease the production of PI3P, which would mani-
fest in decreased DFCP1 vesicles that was observed earlier
(Fig. 1F). Myc knockdown andMyc-I decreased phospho-Bcl2,
consistent with an impairment in autophagy (Fig. 4A and B). To
verify that the effect of Myc-I (10058-F4) on Bcl2 phosphoryl-
ation was not due to an unspecific effect of the drug that is
unrelated to autophagy, another Myc inhibitor (10074-G5) was
used. 10074-G5 targets a region of Myc that is different from
Myc-I (10058-F4).We confirmed that 10074-G5 also decreased
Bcl2 phosphorylation, in parallel with decreased LC3-II levels
(Supplementary Material, Fig. S3).
The effect of Myc knockdown on LC3-II was abrogated
when Bcl2 was inhibited with HA14-1, a BH3 mimetic that
interferes with the inhibitory Bcl2–Beclin 1 interaction, and
thus, would be expected to mimic the functional effects of
Bcl2 phosphorylation in this context (34). This rescued the de-
crease in autophagy that would otherwise be expected with
Myc knockdown, suggesting that Bcl2 is downstream of Myc
(Fig. 4C). In conclusion, these data suggest that the effects of
Myc depletion on autophagy were mediated through changes
in Bcl2 phosphorylation.
To further investigate the molecular mechanism involved
inMyc-modulated autophagy,we examined potentialmolecular
players upstream of Bcl2. Activation of JNK1 has been reported
to phosphorylate Bcl2, thereby inducing autophagy in cells
under starvation conditions (6). Hence, we examined the role
of JNK1 in Myc-dependent Bcl2 phosphorylation and auto-
phagy. Specifically, we studied whether the changes in Bcl2
phosphorylationwas a consequenceof changes in JNK1activity.
We observed that Myc knockdown led to a reduction in JNK1
phosphorylation, and this occurred in parallel with decreased
phosphorylation of Bcl2 (Fig. 5A). Correspondingly, Myc-I
treatment decreased the amount of JNK1 being phosphorylated
(Fig. 5B). Consistent with the literature (35), LC3-II levels were
found to be lower in HeLa cells treated with a JNK inhibitor
(JNK-Inh), and this was associated with decreased phospho-Bcl2
(Supplementary Material, Fig. S4A). JNK-Inh also decreased
LC3-II levels in Myc WT rat fibroblasts (Fig. 5C). JNK-Inh
further loweredLC3-II levels even inMyc2/2 fibroblasts, sug-
gesting that JNK1 acts downstreamofMyc inmodulating autop-
hagy. To confirm the hypothesis that JNK1 is downstream of
Myc in autophagy regulation, JNK1 knockout (2/2) and its
control (JNK +/+) MEFs were used. Myc-I could decrease
LC3-II levels in JNK +/+ MEFs, but this effect was abolished
in JNK 2/2MEFs (Fig. 5D). In addition, we showed that tran-
sient overexpression of constitutively active JNK1 in HeLa
cells could rescue the levels of LC3-II that would otherwise be
decreased inMyc knockdown cells, suggesting that constitutive
JNK1 could abolish the effect of Myc depletion on autophagy,
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perhaps by overriding the decreased JNK phosphorylation
resulting from Myc knockdown (Supplementary Material,
Fig. S4B). These data supported the notion that Myc depletion
led to autophagy impairment through decreased JNK activity
and phosphorylation of its downstream target, Bcl2.
Phosphorylation of Bcl2 by JNK1 has previously been shown
to result in dissociation of Bcl2 from Beclin 1, thereby relieving
Beclin 1 from its inhibitory interaction with Bcl2 and allowing
Beclin 1 to activate autophagy via Vps34 (6). We therefore
tested whether the decrease in autophagy observed withMyc in-
hibition is associatedwith alteredBcl2-Beclin interactions.Con-
sistent with decreased autophagy mediated through a reduction
in phospho-Bcl2 and phospho-JNK1, Myc inhibition increased
the interaction between Bcl2 and Beclin 1 (Fig. 5E).
In addition, as activation of JNK1 has been shown to induce
autophagyunder starvationconditions,wewenton to investigate
if Myc inhibition has the same effect on autophagy during star-
vation. While starvation clearly induced autophagy compared
Figure2.SuppressionofMYCblocks clearanceof autophagy substrates. (A)HeLacells subjected to control orMyc siRNAknockdownfor 72 hwere assessed for p62
levels bywestern blotting.Graph shows quantification of p62/actin ratio. The values represent themean+SEM. ∗P, 0.05. (B) U2OS cellswith stable expression of
Halotag-p62were labelledwith ligand then treatedwith 60 mMMyc-I orDMSO for 16 h. Cellswere lysed and assessed forHalotag-p62 levels by SDS-PAGE relative
to the expression of total protein. Graph shows quantification of labelled p62/total protein ratio. The values represent the mean+SEM of the percentage of labelled
p62/total protein from a triplicate experiment representative of three independent studies. ∗∗P , 0.005. (C) Hek293 cells with tetracycline-inducible expression of
GFP-p62were subjected to control orMyc siRNAknockdown for 72 h. Expression of GFP-p62was inducedwith tetracycline 48 h after transfection and ‘turned off’
after 24 h. Cellswere collected at the time of ‘turn-off’ (t ¼ 0) and 24 h after ‘turn-off’ (t ¼ 24) to assess for clearance ofGFP-p62 bywestern blotting. ∗P , 0.05. (D)
Hek293 cells with tetracycline-inducible expression of GFP-p62was inducedwith tetracyclin and ‘turned off’ after 24 h, followed by treatment with 60 mMMyc-I or
DMSOfor 16 h. Cellswere assessed for clearance ofGFP-p62 bywestern blotting. ∗P , 0.05. (E andF) HeLa cellswere transiently transfectedwith tau recombinant
constructs containing the Dendra tag. After 24 h, Dendra-tau expressed in the cells were either converted by exposure to 405 nm light source for 2 min or left uncon-
verted. (E) Both converted andunconverted cellswere subjected to control orMyc siRNAknockdown for 48 h.Cellswere fixed and assessed for clearance ofDendra-
tau byFACSanalysis.Graph shows the average of themean red fluorescence of three independent studies. (F) Both converted and unconverted cellswere treatedwith
60 mMMyc-I, 200 nMBafA1orDMSOfor 16 h.Cellswerefixed andassessed for clearanceofDendra-taubyFACSanalysis.Graph shows the averageof themean red
fluorescence of three independent studies. ∗P , 0.05; ∗∗∗P , 0.0005.
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to nutrient-replete full medium, it did not increase the number of
GFP-LC3 dots in cells treated with Myc-I (Supplementary Ma-
terial, Fig. S4C). The extent of autophagy inhibition caused by
Myc-I treatment in starvation conditions appears to be greater
than the magnitude of autophagy inhibition in full medium con-
dition because starvation is capable of increasing autophagy.
Similar to Myc-I, treatment with JNK-Inh failed to trigger
starvation-induced autophagy, consistent with the notion that
the effects of Myc inhibition on autophagy are mediated
through JNK activation.
JNK1 is a member of the MAPK family which is activated by
various stress signals, including oxidative stress, UV irradiation
and injury stress associated with pro-inflammatory cytokines
(36). Thus, we also examined the effects of Myc suppression
on other members of the MAPK family, including p38 MAPK
and ERK. However, we did not observe any significant changes
in the phosphorylation levels of p38 MAPK or ERK after Myc
knockdown (Supplementary Material, Fig. S5A).
In addition, recentworkhas demonstrated that the superoxide-
inducing agent, menadione, strongly enhanced autophagy (37).
As oxidative stress related to reactive oxygen species (ROS) sig-
nalling has been known to regulate autophagy (38,39), andMyc
is known to induce ROS accumulation, we therefore examined
the role of ROS in modulation of autophagy resulting from
Myc suppression. We found that Myc knockdown cells con-
tained lower levels of ROS in assays with 6-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) or
MitoSOXTM red (Fig. 6A andB). Consistent with this, treatment
with hydrogen peroxide nullified the effect of Myc knockdown
on autophagy and restored LC3-II levels comparable with con-
trols (Supplementary Material, Fig. S5B).
Inhibition ofMyc has been shown to trigger cell growth arrest
and apoptosis in transformed cells as well as tumour xenografts
(18–20). Thus, we examined the consequences of autophagy-
lysosome inhibition in the context ofMyc suppression inhibition
on cancer cell survival (Fig. 6C) by assessing the effects of in-
creasing dosage ofMyc-I on cell viability in the absence or pres-
ence of Baf A1.Myc-I clearly decreased cell viability compared
with control. The extent of reduction in cell viability in response
to Myc-I treatment was dose-dependent without Baf A1. The
presence of Baf A1 consistently resulted in a lower cell viability
compared with cells without Baf A1 at lower concentrations of
Myc-I. Intriguingly, when autophagy was inhibited with Baf
A1 treatment, the presence of Myc-I only minimally decreased
cell viability from 0 to 60 mM. Our data indicate that autophagy-
lysosome attenuation with Baf A1 decreased cell viability itself
and delayed the onset of response towards Myc-I in terms of in-
hibition of cell viability. This also implies that the effects ofMyc
inhibition on cell viability were at least partially dependent on
the autophagy-lysosome pathway.
Collectively, our data suggest that Myc knockdown, through
decreased generation of ROS, resulted in less phosphorylation
of JNK1 and Bcl2, which consequently led to a reduction in
autophagy (Fig. 6D).
DISCUSSION
Myc plays important roles in many fundamental aspects of cell
biology, such as cell proliferation, differentiation and sensitivity
to apoptosis (40). Our study identifies a novel function ofMyc in
autophagy, a process important for the maintenance of cellular
homeostasis. Myc knockdown impaired autophagy through
decreased phosphorylation of JNK1 and its downstream target
Bcl2. The functional relevance of this observation reinforces
the attractiveness of targeting Myc as a therapeutic strategy for
cancers, since autophagy promotes cell survival under stress
conditions, such as nutrient depletion and hypoxia, often
encountered by established tumour cells.
Figure 3.MYCeffects on autophagy are independent ofmTOR.HeLa cells sub-
jected to control or Myc siRNA knockdown for 72 h were assessed for (A)
phospho- and total S6K; (B) phospho- and total S6 levels by western blotting.
Figure4.MYCknockdowndecreasesLC3-II levels via a reductionofBcl2phos-
phorylation. (A) HeLa cells subjected to control or Myc siRNA knockdown for
72 h were assessed for phospho-Bcl2 levels by western blotting. (B) HeLa
cells treated with 60 mM Myc-I for 8 h were assessed for phospho-Bcl2 levels
by western blotting. (A and B) Graphs show quantification of the phospho-
Bcl2/total Bcl2 ratio. The values represent the mean+SEM of the percentage
of phospho-Bcl2/total Bcl2 from three independent experiments. ∗∗P , 0.005;
∗∗∗P , 0.0005. (C) HeLa cells subjected to control or Myc siRNA knockdown
for 72 h were treated with 20 mM HA14–1, a Bcl2 inhibitor or DMSO for the
last 16 h. Graph shows quantification of the LC3-II/actin ratio. The values repre-
sent the mean+SEM of the percentage of LC3-II/actin from three independent
experiments. ∗∗P, 0.005; NS, not significant.
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Previously, the anti-neoplastic effect of Myc inactivation has
been associated with mechanisms such as proliferative arrest,
cellular senescence, terminal differentiation and apoptosis in-
duction (18,19). None has directly linked the effects of Myc de-
pletion with decreased autophagy. In fact, earlier studies have
shown that cancer cells have decreased autophagic activity and
increased accumulation of the autophagic substrates p62 (41).
In addition, tumour suppressors such as Beclin 1, PTEN and
DAP kinase are known to positively regulate autophagy (42).
Therefore, one would expect an oncogene to have inhibitory
effects on autophagy. Following this, Myc depletion would be
expected to induce autophagy. On the contrary, we showed
that Myc knockdown decreased autophagy. This is further con-
firmed by inhibition of Myc with small molecule inhibitors,
10058-F4 and 10074-G8, which target different regions of
Myc, and both resulted in impaired autophagy as well as
decreased Bcl2 activity.
Previously, autophagy inhibition with chloroquine has been
demonstrated to promote apoptosis and tumour regression in a
Myc-induced lymphoma model (43). The study suggested that
autophagy is an adaptive response to enhance the survival of
tumour cells in the face of apoptotic insults. It was therefore pro-
posed that apoptosis activators can potentially be used in com-
bination with autophagy inhibitors to enhance its therapeutic
effects in human cancers. Consistent with their data, we found
that inhibition of autophagywith BafA1 decreased cell viability
compared with cells without treatment. In addition, we showed
that treatment with Myc-I, which inhibits autophagy, reduced
cell viability in a dose-dependent manner. Myc presents an at-
tractive target for cancer therapy asMyc suppressionbydifferent
strategies has been shown to induce cell growth arrest and apop-
tosis in transformed cells, as well as tumour regression in
Myc-induced cancers (18,19). In light of our data presented
here, work by Amaravadi and colleagues lends further support
Figure 5.MYCknockdowndecreasesBcl2 activity via a decrease in JNK activity. (A) HeLa cells subjected to control orMyc siRNAknockdown for 72 hwere probed
with the indicated antibodies bywestern blotting. (B) HeLa cells treatedwith 60 mMMyc-I for 8 hwere assessed for phospho-JNK levels bywestern blotting. (A andB)
Graphs showquantification of the phospho-JNK/total JNK ratio. The values representmean+SEMof the percentage of phospho-JNK/total JNK from three independ-
ent experiments. ∗P, 0.05; ∗∗∗P, 0.0005. (C)Myc+/+ (WT) orMyc2/2rat fibroblasts treatedwith 20 mM JNK inhibitor VIII (JNK-Inh) for 3 hwere assessed for
LC3-II levels by western blotting. (D) JNK+/+ or JNK2/2MEFs treated with 60 mMMyc-I for 16 h were assessed for LC3-II levels by western blotting. (C andD)
Graphs showquantificationof theLC3-II/actin ratio.The values representmean+SEMof the percentage of theLC3-II/actin ratio from three independent experiments.
∗P, 0.05; ∗∗P, 0.005; ∗∗∗P, 0.0005; NS, not significant. (E) HeLa cells co-transfectedwithBeclin 1 andBcl2 or empty vector expression constructs for 24 hwere
treated with DMSO (control) or 60 mMMyc-I for the last 8 h before being harvested. Lysates were subjected to IP with Beclin 1 antibody (as described in theMethods
section) and then assessed for Bcl2 levels by western blotting. Arrow indicates Bcl2 band.
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to targeting Myc as an anti-neoplatic strategy, especially in
Myc-induced tumours, as this might confer the additional
benefit of inhibiting autophagy in the case of therapy resistance
associated with chemotherapy-induced autophagy. Furthermore,
our data suggest that one of the added benefits of Myc inhibition
in the tumour context is autophagy compromise.
Elucidation of the molecular mechanisms involved in Myc
regulationofautophagy is important forunderstandingof the feasi-
bility andpotential side effects that could arise from inactivationof
Myc and its affected downstream targets. The closest observation
wasmade byTsuneoka and colleagues using a stable inducible ex-
pressionof theMycERsystem in rat 3Y1fibroblasts (44),whereby
they reported that the overexpression of Myc was correlated with
increased autophagic vacuoles. However, increase in autophagic
vacuoles (or LC3-II) does not necessarily reflect an increase in
autophagicflux–itmaybea result of ablock in theautophagosome
degradation step, thus leading to an accumulation of autophago-
somes. In addition, overexpression of Myc to non-physiological
levels may lead to artefacts and confounding results. Different
from their approach and in linewith the relevance ofMyc inactiva-
tion as an anti-neoplastic strategy, we showed that Myc knock-
down decreases autophagosome formation. We also elucidated
JNK1 and Bcl2 phosphorylation as plausible effectors involved
in the regulation of autophagy by Myc suppression, and that this
is likely mediated through changes in downstream Bcl2–
Beclin1 interactions.
In addition to the plausible pathway that we have character-
ized in this study, we cannot exclude the possibility that there
are other indirect pathways involved as well. Although decrease
inROS is expected to affect othermembers of theMAPKfamily,
p38MAPKandERKwerenot significantly affected byMyc sup-
pression, perhaps due to other compensatory mechanisms
causedbychanges inMyc activity (45).Nonetheless, our data in-
dicate that regulations of JNK1 and Bcl2 are key consequences
impacting on autophagy that result fromMyc inhibition. In con-
clusion, our data provide mechanistic insights not only into the
Figure 6.ROS levels were lower inMYCknockdown cells. HeLa cells subjected to control orMyc siRNAknockdown for 72 hwere assessed for total ROS levels by
FACS analysis of (A) carboxy-H2-DCFDA (a representative histogram of carboxy-H2-DCFDA fluorescence measurement by FACS analysis is shown); and (B)
MitoSoxTM red fluorescence. Graphs show mean+SEM of mean geometric fluorescence of three independent studies, in which the control condition has been
set to 100. ∗P, 0.05; ∗∗P , 0.005. (C) HeLa cells treated with 200 nM Baf A1 were co-treated with different concentrations of Myc-I as indicated for 16 h. Cells
were assessed for viabilitywithCellTiter-Glo luminescent assay (as described in theMethods section).Graph showsmean+SEMofmean luminescence (in relative
fluorescence unit, RLU) from a triplicate experiment representative of three independent studies. (D) Schematic illustrating the pathway involved in regulation of
autophagy resulting from Myc depletion: Myc suppression is associated with decreased ROS production, which leads to reduced phosphorylation of JNK1 and its
downstream target, Bcl2, thereby inhibiting autophagy.
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association between Myc and autophagy, but also into the func-
tional relevance thatMyc suppression has in the development of
potential cancer therapy.
MATERIALS AND METHODS
Cell culture
HeLa cells, HEK293 cells, WT TGR-1 (Myc WT) and c-Myc
null HO15.19 (Myc 2/2) rat fibroblast cell lines (generous
gift of J.M. Sedivy) (46), Atg5 2/2 MEFs (kindly provided
by N. Mizushima) (47) , and JNK1 2/2 MEFs (kind gift of
R.J. Davies) (48) were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM, Sigma) supplemented with 10% Fetal
Bovine Serum (FBS, Sigma), 2 mM L-glutamine and 100 U/ml
penicillin/streptomycin at 378C in 5% CO2. HeLa cells stably
expressing the GFP-LC3 (kind gift of A.M. Tolkovsky) (49)
and HEK293 stably expressing GFP-DFCP1 (kindly provided
by N.T. Ktistakis) (28) were cultured in a similar medium con-
taining 500 mg/ml G418. Stable inducible GFP-p62 HEK293
cells (from T. Johansen) (50) were cultured as above, with the
addition of 100 mg/ml hygromycin B (Calbiochem) and
7.5 mg/ml blasticidin (Invitrogen) to the culture medium.
Cells were seeded 24 h before transfection such that they
reached 70–80% confluency the next day. cDNA constructs
or siRNA were transfected using Lipofectamine 2000 reagent
(Invitrogen) in OptiMEM (Invitrogen) by following the manu-
facturer’s protocols. pcDNA3.1 empty vector was used as a
control in overexpression studies, whereas nontargeting siRNA
was used in siRNA experiments (SMARTpool; Thermo Fisher
Scientific).
DNA constructs
The cDNA constructs used in transfection were obtained from
the following sources: pcDNA3-c-Myc from W. El-Deiry
(Addgene plasmid 16011) (51), and Flag-CA JNK1 (Flag-
MKK7B2Jnk1a1) from R.J. Davis (Addgene plasmid 19726)
(51). Dendra-tau was obtained by subcloning WT human
MAPT (2N4R) in pcDNA3.1 (a gift from L. Gan) (52) into
pDendra2 vector (Evrogen) at KpnI and ApaI sites. Beclin 1
and Bcl2 plasmids were described earlier (53).
Reagents
All chemicals used in this studywere dissolved in dimethyl sulf-
oxide (DMSO) unless otherwise stated. The following chemical
compounds were used for treatment at the following concentra-
tions: bafilomycin A1 (400 nM, Millipore), 10058-F4 (60 mM,
Calbiochem), 10074-G5 (30 mM, Sigma), HA14-1 (20 mM,
Sigma), JNK inhibitor VIII (20 mM, Calbiochem), Carboxy-H2-
DCFDA (20 mM, Invitrogen) and MitoSOXTM red (5 mM, Invi-
trogen).
Primary antibodies used were: rabbit anti-c-Myc (diluted at
1:1000, Santa Cruz), rabbit anti-LC3 (diluted at 1:2000, Novus
Biologicals), rabbit anti-actin (diluted at 1:2000, Sigma), mouse
anti-a-tubulin (diluted at 1:5000, Sigma), mouse anti-GFP
(diluted at 1:5000, Clontech), rabbit anti-phospho-Bcl2 (diluted
at 1:1000, Cell Signalling), rabbit anti-Bcl2 (diluted at 1:1000,
Santa Cruz), rabbit anti-phospho-JNK (diluted at 1:1000, Cell
Signalling), mouse anti-JNK (diluted at 1:1000, Santa Cruz),
rabbit anti-Beclin1 (diluted at 1:1000, Cell Signalling), mouse
anti-p62 (diluted at 1:1000, BD transduction Laboratories),
rabbit anti-phospho-S6K (diluted at 1:1000, Cell Signalling),
rabbit anti-S6K (diluted at 1:1000, Cell Signalling), rabbit
anti-phospho-S6 (diluted at 1:1000, Cell Signalling) and rabbit
anti-S6 (diluted at 1:1000, Cell Signalling).
Western blot analysis
Assessment of protein levels was carried out by standard sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–
PAGE) and western blotting techniques. In brief, cells were
lysed in radioimmunoprecipitation assay (RIPA) buffer
[150 mM sodium chloride, 1% (w/v) sodium deoxycholate,
50 mM Tris (pH 7.4), 1% (v/v) Triton X-100, 0.25 mM EDTA,
5 mM sodium orthovanadate, 50 mM sodium fluoride, phosphat-
ase inhibitor and protease inhibitor (RocheMolecular Biochem-
icals)] and the supernatant was collected for analysis by
immunoblotting. To ensure equal loading of samples, protein
concentration was determined by using a DC protein assay
(Biorad) before being subjected to a SDS–PAGE.
Blots were probed with primary antibodies overnight fol-
lowed by horseradish peroxidase-conjugated anti-mouse or anti-
rabbit IgG (Roche) at 1:5000. Protein bands were detected using
an enhanced chemiluminescence (ECL)western blotting kit (GE
Healthcare) and densitometry quantified using ImageJ software
(National Institutes of Health).
Autophagy assesment by automated cellomics microscope
HeLa cells stably expressing GFP-LC3 were cultured on cover-
slips and subjected to siRNA knockdown or drug treatment.
They were then rinsed once with phosphate-buffered saline
(PBS) andfixedwith 4%paraformaldehyde, followed bymount-
ing of coverslips on slides using Prolong Gold antifade reagent
with 4’, 6-diamidino-2-phenylindole (Invitrogen). The number
of GFP puncta per cell was quantified with the Spot detector
V3 Cellomics Bioapplication in a Thermo Scientific Cellomics
ArrayScan High Content Screening Reader. At least 300 cells
were scored for each sample and the average number of dots
per cell was computed by the ArrayScan software.
HaloTag-p62 clearance assay for autophagy activity
U2OS cells stably expressing HaloTag-p62 (construct was
obtained from Kazusa DNA Research Institute collection) (pre-
viously described in (54)) were cultured in DMEM supplemen-
ted with 10% FBS (Sigma), 2 mM L-glutamine, 100 U/ml
streptomycin/penicillin and 100 mg/ml hygromycin B at 37 8C,
5% CO2. To assay for p62 clearance, cells were seeded in
12-well plates and the next day, they were labelled with a
diAcFam-conjugated fluorescent HaloTag ligand (Promega)
according to manufacturer’s instructions. Labelled cells were
subsequently treated with Myc-I (60 mM) or DMSO as a control
for 16 hbefore being harvested as described above and subjected
to SDS–PAGE. Gels were scanned and fluorescence was mea-
sured with a Typhoon 8600 imager. For quantification of total
protein loading, Krypton Flourescent Protein Stain (Pierce)
was used following the manufacturer’s instructions.
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Fluorescence levels were quantified by densitometric analysis
using Image J software.
Dendra-tau clearance assay
Dendra-tau was transfected into HeLa cells with Lipofectamine
2000. After 24 h, Dendra-tau was either photoconverted from
green to red by exposure of cells to a 405 nm LED light source
(constructed in-house) for 2 min or left unconverted (as con-
trols). Both converted and unconverted cells were subjected to
control or Myc siRNA knockdown for 48 h before being fixed
and analysed by fluorescence-activated cell sorting (FACs) for
Dendra-tau levels. The red fluorescent signal was assessed at
excitation and emission wavelengths of 561/586 using a FACS
analysis BD LSR Fortessa cell analyser (BD Biosciences).
For compound treatment, cells were similarly photoconverted
prior to treatment with the various drugs for 16 h before being
analysed by FACS.
Immunoprecipitation
Cells collected for immunoprecipitation (IP) studywere lysed in
BufferA (20 mMTris–HCl, pH7.4, 2 mMMgCl2, 150 mMNaCl,
5 mMNaF, 1 mMNa3VO4, 0.5%NP-40, protease inhibitor cock-
tail (Roche)) for 20 min on ice, followed by centrifugation at 13
000g for 15 min. Cell lysates were incubatedwith an anti-Beclin
1 antibody (Cell Signalling) overnight at 48C, and subsequently
with Dynabeads Protein G (Invitrogen) for 3 h at 48C. Products
of IP were boiled in Laemmli buffer and analysed by western
blotting.
ROS assay
HeLa cells were monitored for intracellular ROS genera-
tion using a peroxide-sensitive fluorescent probe, 2′, 7′-dichlor-
ofluorescin diacetate (Carboxy-H2DCFDA); or mitochondrial
superoxide sensitive dye, MitoSOXTM. After 72 h of siRNA
knockdown, cells were washed once with PBS and incubated
with phenol red-free complete medium (Gibco) containing
20 mM carboxy-H2DCFDA for 20 min or 5 mM MitoSOX
TM
red (Invitrogen) for 10 min at 378C. Subsequently, cells were
harvested with trypsin and washed twice with phenol red-free
medium. Following this, they were resuspended in phenol
red-free medium. The fluorescent signal was assessed at excita-
tion and emissionwavelengths of 488/530 using a FACSCalibur
flow cytometer (Beckman Coulter, California, USA) for
carboxy-H2DCFDA and using a BD LSR Fortessa cell analyser
(BDBiosciences) forMitoSOXTM red.At least 10 000 cellswere
measured for each sample. Data were analysed using the FlowJo
software (Tree Star, Inc.) and presented as the geometricmean of
green fluorescence for carboxy-H2DCFDA or red signal for
MitoSOXTM red.
Cell viability assay
Cell viabilitywas determined byusing aCellTiter-GloLumines-
cent Cell Viability Assay kit (Promega) following the manufac-
turer’s instructions.Briefly, 100 ml ofCellTiter-Glo reagentwas
added to cells grown in 100 ml of culture medium in a 96-well
plate. The contents were mixed on a shaker for 5 min and
incubated at room temperature for 10 min. Luminescence was
then measured with a GloMax luminometer (Promega).
Statistical analyses
Immunoblots were quantified by densitometric analysis with
the Image J program (Rasband,W.S., ImageJ,USNational Insti-
tutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/,
1997–2005). Protein signalswere normalized to actin as loading
control. The P-values were determined by two-tailed Student’s
t-test in at least three independent experiments. Statistical sig-
nificance for comparisons between more than two groups was
analyzed by one-way ANOVA with a Dunnett or Bonferroni
multiple comparisons post hoc test in PRISM software.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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